Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBPNASDAQ:KINNYSE:LCINASDAQ:NERVNASDAQ:STML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$7.61-1.8%$7.75$4.64▼$61.90$94.35M3.05343,453 shs77,721 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsNERVMinerva Neurosciences$1.70-1.7%$1.68$1.15▼$3.50$11.54M-0.3422,922 shs3,539 shsSTMLStemline Therapeutics$11.83$11.83$3.21▼$18.22$621.21M1.781.52 million shs1,084 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%+2.81%-13.55%+51.55%-84.68%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%LCILannett0.00%0.00%0.00%0.00%0.00%NERVMinerva Neurosciences0.00%-4.49%-5.82%+24.09%-45.86%STMLStemline Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals3.7867 of 5 stars3.60.00.04.70.92.50.6KINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.1583 of 5 stars3.04.00.04.60.00.01.3STMLStemline TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 3.10Buy$50.88568.70% UpsideKINKindred Biosciences 0.00N/AN/AN/ALCILannett 0.00N/AN/AN/ANERVMinerva Neurosciences 2.00Hold$5.00194.12% UpsideSTMLStemline Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LCI, STML, CRBP, NERV, and KIN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AKINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29LCILannett$340.58M0.00N/AN/A($23.34) per share0.00NERVMinerva NeurosciencesN/AN/A$0.22 per share7.90($3.67) per shareN/ASTMLStemline Therapeutics$43.22M14.37N/AN/A$3.26 per share3.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/ALCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ANERVMinerva Neurosciences$1.44M$0.822.07N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)STMLStemline Therapeutics-$76.82M-$1.83N/AN/AN/A-150.30%-48.14%-41.35%N/ALatest LCI, STML, CRBP, NERV, and KIN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ASTMLStemline TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A11.8211.82KINKindred Biosciences0.197.027.02LCILannettN/A2.231.39NERVMinerva NeurosciencesN/A9.219.21STMLStemline TherapeuticsN/A7.437.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%KINKindred Biosciences66.89%LCILannett40.28%NERVMinerva Neurosciences34.56%STMLStemline Therapeutics75.80%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.60%KINKindred Biosciences13.69%LCILannett13.12%NERVMinerva Neurosciences8.60%STMLStemline Therapeutics11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4012.24 million11.80 millionOptionableKINKindred Biosciences6345.46 millionN/AOptionableLCILannett81010.77 million9.35 millionOptionableNERVMinerva Neurosciences96.99 million6.39 millionNot OptionableSTMLStemline Therapeutics9252.51 millionN/AOptionableLCI, STML, CRBP, NERV, and KIN HeadlinesRecent News About These CompaniesInsilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M dealJanuary 10, 2025 | fiercebiotech.comFMenarini bags blood cancer drug with $677M Stemline acquisitionAugust 5, 2024 | pharmaphorum.comPMenarini Group and Insilico Medicine Enter Global Exclusive License Agreement forJanuary 6, 2024 | newswire.caMenarini Group’s Stemline inks $500M+ biobucks deal for Insilico’s breast cancer candidateJanuary 4, 2024 | fiercebiotech.comFStemline Therapeutics describes new RET mutant inhibitors for cancerMay 6, 2023 | bioworld.comBNew Hormonal Treatment Orserdu Approved for Metastatic Breast CancerFebruary 19, 2023 | everydayhealth.comEStemline Therapeutics’ breast cancer treatment approvedFebruary 1, 2023 | labiotech.euLFDA Approves Stemline’s Orserdu for Several Forms of Breast CancerJanuary 31, 2023 | fdanews.comFStemline first to market with oral SERD for breast cancerJanuary 31, 2023 | pharmaphorum.comPTrade These 7 Stocks Under $10 for Huge ProfitsApril 10, 2022 | thestreet.comBreakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)October 26, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCI, STML, CRBP, NERV, and KIN Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$7.61 -0.14 (-1.83%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$7.60 0.00 (-0.04%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Lannett NYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Minerva Neurosciences NASDAQ:NERV$1.70 -0.03 (-1.73%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Stemline Therapeutics NASDAQ:STMLStemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
